Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 17, 2009 Acorda Therapeutics to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results on February 24, 2009
HAWTHORNE, N.Y.--([ BUSINESS WIRE ])--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it will report its financial results for the fourth quarter and full year ended 2008 on Tuesday, February 24, 2009 at 8:30 a.m. ET before the U.S. financial markets open.
In conjunction with the press release, the Company will also host a conference call and live audio webcast at 8:30 a.m. ET on Tuesday, February 24, 2009 to discuss the Company's financial results for the fourth quarter and full year ended 2008.
To participate in the conference call, please dial 866-700-6979 (domestic) or 617-213-8836 (international) and reference the access code 27093206. The presentation will be available via a live webcast at [ http://phoenix.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=194451&eventID=2097807 ]. A replay of the call will be available from 10:30 a.m. ET on February 24, 2009 until midnight on March 26, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 11467599. The archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at [ http://www.acorda.com ].
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda filed a New Drug Application (NDA) for its lead clinical product, Fampridine-SR, on January 30, 2009. Clinical trials of Fampridine-SR evaluated its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including delays in obtaining or failure to obtain FDA approval of Fampridine-SR, the risk of unfavorable results from future studies of Fampridine-SR, Acorda Therapeutics' ability to successfully market and sell Fampridine-SR, if approved, and Zanaflex Capsules, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
